Novartis AG Announces Stellar Second Quarter Performance

In a remarkable display of financial health, Novartis AG reported a 12% increase in net sales for the second quarter of fiscal year 2025, totaling $14.05 billion. This growth underscores the company's robust position in the pharmaceutical industry.

Financial Highlights

The company's net income saw a significant 24% rise to $4.02 billion, with operating income also jumping by 21% to $4.86 billion. Earnings per share (EPS) advanced by 29% to $2.07, and core EPS soared by 23% to $2.42, compared to the same period last year.

Leadership's Perspective

CEO Vas Narasimhan expressed optimism, stating, "Novartis delivered another strong quarter, with double-digit sales and core operating income growth. Our ongoing launches for Kisqali, Pluvicto, and Scemblix are performing exceptionally well, showcasing the dynamic replacement power within our portfolio."